Werewolf Therapeutics Inc(HOWL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.74 | Insider Own | 17.84% | Shs Outstand | 48.6M | Perf Week | 8.91% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | 33.71% | Insider Trans | -32.99% | Shs Float | 39.9M | Perf Month | 19.27% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | -0.22 | Inst Own | 22.06% | Short Float | 5.9% | Perf Quarter | 211.53% |
| Income | -0.03B | P/S | 2.55 | EPS this Y | 33.08% | Inst Trans | 26.72% | Short Ratio | 0.35 | Perf Half Y | 52.86% |
| Sales | 0.02B | P/B | 3.28 | EPS next 5Y | - | ROA | -59.31% | Short Interest | 2.36M | Perf YTD | 73.64% |
| Book/sh | 0.34 | P/C | 2.43 | EPS past 3/5Y | 10.71% -6.15% | ROE | -119.86% | 52W High | -32.1% ($1.62) | Perf Year | -29.49% |
| Cash/sh | 0.45 | P/FCF | - | Sales past 3/5Y | - | ROIC | -212.45% | 52W Low | 307.41% ($0.27) | Perf 3Y | -55.28% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 55.37% | Gross Margin | 82.61% | Volatility(W/M) | 6.07% 5.25% | Perf 5Y | -92.98% |
| Dividend TTM | - | EV/Sales | 1.5 | Sales Y/Y TTM | -100% | Oper. Margin | -121.78% | ATR (14) | 0.05 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.91 | EPS Q/Q | 118.88% | Profit Margin | -164.82% | RSI (14) | 68.54 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.91 | Sales Q/Q | - | SMA20 | 11.06% ($0.99) | Beta | 0.57 | Target Price | $4 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/7/31 | SMA50 | 14.98% ($0.96) | Rel Volume | 0.06 | Prev Close | $1.06 |
| Employees | 39 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 61.84% ($0.68) | Avg Volume(3M) | 6.64M | Price | $1.1 |
| IPO | 2021/4/30 | Option/Short | Yes/Yes | Trades | 726 | Volume | 400,928 | Change | 3.77% |
A clinical-stage biotech developing cancer immunotherapies. Using its proprietary PREDATOR® platform-based INDUKINE technology, the company develops cytokine therapeutics that are selectively activated only in the tumor microenvironment. WTX-124 (IL-2), targeting melanoma, has received FDA Fast Track designation, and WTX-330 (IL-12), targeting solid tumors, is also in clinical development.
Over the past 1 year, roughly in the middle
32% below its 1-year high.
Traded less than usual. That is 6% of its average volume.
HOWL has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +33.1% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $255. Peers typically go for $1,089.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -93.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 22.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #411 of 594 in the industry
Based on market cap of $53M.
ALPS#410 ALPS Group Inc $54M PER - HOWL#411 Werewolf Therapeutics Inc $53M PER - 
ELOX#412 Eloxx Pharmaceuticals Inc $53M PER - 
PLRX#413 Pliant Therapeutics Inc $53M PER - 
CNTB#414 Connect Biopharma Holdings Ltd $53M PER - 
FAQ
What kind of company is HOWL?
HOWL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of HOWL?
The market cap of HOWL is approximately $53M, ranking 4,822 within its sector.
What is the 52-week high and low for HOWL?
HOWL has recorded a 52-week high of $1.62 and a low of $0.27.
